Metabolic Disease
| 4 min read
Provention Bio advances work on coxsackievirus B vaccine
| 2 min read
Patients treated with efruxifermin show improvements in markers of insulin sensitivity and lipoprotein metabolism
| 3 min read
Although primary endpoint was reached, the results were “unremarkable” and the company is discontinuing further development
